I remain optimistic that Remestemcel will become SOC in ICU Departments soon. Fingers crossed sooner than later.
IMO you should temper your expectations in this regard unfortunately but each to their own
On the current COVID-19 death figures basically 28,000 people have died in the USA in the last 14 days - even as these death numbers spiral well before the fall and represent more than double last years figures for the same period, I haven't seen the FDA, NIH or BARDA running to Mesoblast to get Remestemcel-L into hospitals ... instead they are happy to wait for the OTAT meeting sometime next quarter and move at a snails pace from there
In the interim the FDA have also knocked back a couple of EUA's recently so again I would assume that these USA government organisations are happy with the current regime of approved drugs and therapies to deal with COVID-19 and by default are ok with these types of death numbers ? Crazy I know, but that is how it appears on the surface to me
MSB Price at posting:
$1.64 Sentiment: Hold Disclosure: Held
(20min delay)